TrialThe oncologist2012

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

Patricia Pautier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.